ACC010, a novel BRD4 inhibitor, synergized with homoharringtonine in acute myeloid leukemia with FLT3 ‐ITD

Bromodomain‐containing protein 4 (BRD4) inhibitors have been clinically developed to treat acute myeloid leukemia (AML), but their application is limited by the possibility of drug resistance, which is reportedly associated with the activation of the WNT/β‐catenin pathway. Meanwhile, homoharringtoni...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Yu, Zhang, Xiang, Mao, Shihui, Wei, Wenwen, Lin, Xiangjie, Ling, Qing, Ye, Wenle, Li, Fenglin, Pan, Jiajia, Zhou, Yutong, Zhao, Yanchun, Huang, Xin, Huang, Jiansong, Tong, Hongyan, Sun, Jie, Jin, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323884/
https://www.ncbi.nlm.nih.gov/pubmed/36567628
http://dx.doi.org/10.1002/1878-0261.13368

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323884/
https://www.ncbi.nlm.nih.gov/pubmed/36567628
http://dx.doi.org/10.1002/1878-0261.13368

Ejemplares similares